GlassScriptPhysician profile
Patricia L James
NPI 1689693517
$9,068.58
in general payments reported to CMS, 2019-2025
63 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 95% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,856 · 2020: $1,363 · 2021: $1,439 · 2022: $1,068 · 2023: $1,024 · 2024: $1,283 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,342.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,181.79 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,072.34 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Amgen INC. | $957.65 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $478.04 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $462.33 | 2019-2025 | |
| Daiichi Sankyo INC. | $323.38 | 2019-2022 | |
| Abbott Laboratories | $288.67 | 2020-2025 | Freestyle Libre 3, Octrode |
| Abbvie INC. | $284.20 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $226.61 | 2020-2024 | Glassia |
| Merck Sharp & Dohme LLC | $224.40 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $221.14 | 2019-2021 | |
| Astellas Pharma US INC | $211.57 | 2019-2024 | Veozah |
| Novo Nordisk INC | $205.00 | 2020-2025 | Ozempic, Rybelsus |
| Insmed, INC. | $204.54 | 2019-2024 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $203.67 | 2019-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.